预约演示
更新于：2026-03-11
Pamufetinib
更新于：2026-03-11
概要
基本信息
药物类型 小分子化药 |
别名 TAS-115 |
作用方式 拮抗剂、抑制剂 |
作用机制 VEGFR拮抗剂(血管内皮细胞生长因子受体拮抗剂)、c-Met抑制剂(肝细胞生长因子受体抑制剂) |
在研适应症 |
非在研机构- |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H23FN4O4S |
InChIKeyORRNXRYWGDUDOG-UHFFFAOYSA-N |
CAS号1190836-34-0 |
关联
12
项与 Pamufetinib 相关的临床试验JPRN-jRCT2071240021
Clinical pharmacology study to evaluate the effects of food on TAS-115 in healthy subjects
开始日期2024-08-05 |
申办/合作机构- |
JPRN-jRCT2071210113
Clinical pharmacology study to evaluate the drug-drug interactions of TAS-115 in healthy subjects
开始日期2022-03-07 |
申办/合作机构- |
JPRN-jRCT2031210372
Drug-drug interactions study of TAS-115 with pioglitazone, losartan, and midazolam in patients with solid tumors
开始日期2021-12-15 |
申办/合作机构- |
100 项与 Pamufetinib 相关的临床结果
登录后查看更多信息
100 项与 Pamufetinib 相关的转化医学
登录后查看更多信息
100 项与 Pamufetinib 相关的专利（医药）
登录后查看更多信息
13
项与 Pamufetinib 相关的文献（医药）2024-02-11·Journal of biomolecular structure & dynamics
Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening
Article
作者: Meng, Dan ; Zhang, Xiaoxuan ; Xie, Jiali ; Deng, Ping ; Li, Yihao
Vascular endothelial growth factor receptor 2 (VEGFR2) and c-Mesenchymal epithelial transition factor (c-Met) are tyrosine kinase receptors associated with the occurrence of malignant tumors. Studies have shown that inhibition of VEGFR2 promotes a feedback increase in c-Met, a mechanism linked to the emergence of resistance to VEGFR2 inhibitors. Therefore, treatment targeting both VEGFR2 and c-Met will have better application prospects. In this study, hierarchical virtual screening was performed on ZINC15, Molport and Mcule-ULTIMATE databases to identify potential VEGFR2/c-Met dual inhibitors. Firstly, the best pharmacophore model for each target was used to cross-screen the three databases, and the compounds that could match the two pharmacophore models were then retained based on the Fit Value of the respective crystal ligands. Compounds ZINC, MOL, and MLB named after their database sources were retained by binding pattern analysis and docking assessment. ADMET predictions indicated that ZINC had significantly higher oral bioavailability compared to the approved drug cabozantinib. This is likely due to ZINC's unique symmetrical backbone with less structure complexity, which may reduce the occurrence of adverse effects. Molecular dynamics simulations and binding free energy analysis showed that all three hit compounds were able to stably bind at the active site, but only ZINC could form high occupancy of hydrogen bonds with both VEGFR2 and c-Met, and also only ZINC had a higher binding free energy than crystal ligands, suggesting that ZINC was the most likely potential VEGFR2/c-Met dual-target inhibitor. This finding provides a promising starting point for the development of VEGFR2/c-Met dual-target inhibitors.Communicated by Ramaswamy H. Sarma.
2023-07-01·Respiratory investigation
Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis
Article
作者: Takashi Ogura ; Arata Azuma ; Susumu Sakamoto ; Naoki Arai ; Seidai Sato ; Keisuke Tomii ; Koichiro Kamio ; Tomohiro Handa ; Shu Hisata ; Yasuhiko Nishioka ; Hiromi Tomioka ; Sakae Homma ; Yasunari Miyazaki
BACKGROUND:
TAS-115, a novel oral multi-kinase inhibitor, showed antifibrotic effects in in vitro and in vivo animal models of idiopathic pulmonary fibrosis (IPF).
METHODS:
In this exploratory phase 2 study, IPF patients with a percent predicted forced vital capacity (%FVC) decline ≥5% acquired within the previous 6 months were enrolled. Patients were divided into three pre-treatment cohorts, namely, treatment-naïve, pirfenidone, or nintedanib. TAS-115 was administered orally at 200 mg/day with a 5-day on and 2-day off regimen. After 13 weeks of treatment, patients entered a 13-week extension treatment period where the efficacy was evaluated. The primary endpoint was the difference in slope of %FVC decline at Week 13 from baseline. Safety was also evaluated.
RESULTS:
Between June 2018 and July 2019, 46 patients were enrolled, and 30 (65.2%) patients completed the 13-week treatment. Of these, 22 (47.8%) proceeded to extension treatment. For the primary endpoint, TAS-115 treatment lowered the slope of the %FVC decline of 0.0750%/day (95% confidence interval: 0.0341-0.1158%/day) at Week 13. Efficacy was also demonstrated at Week 26. Treatment-related adverse events were reported in 40 (88.9%) patients, but most were manageable by dose reduction, dose interruption, or symptomatic treatment.
CONCLUSIONS:
TAS-115 treatment was effective, assessed using intra-patient change in slope of %FVC decline as a surrogate endpoint in patients with IPF pre-treated with pirfenidone or nintedanib and treatment-naïve patients. TAS-115 showed acceptable tolerability and a manageable safety profile.
TRIAL REGISTRATION:
Japic-Clinical Trials Information, JapicCTI-183898 (first registered: March 15, 2018).
2021-12-01·Investigational new drugs3区 · 医学
Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study
3区 · 医学
Article
作者: Yonemori, Kan ; Yamamoto, Noboru ; Kawai, Akira ; Naka, Norifumi ; Iwata, Shintaro ; Outani, Hidetatsu ; Kitano, Shigehisa ; Kobayashi, Eisuke ; Tamiya, Hironari ; Takahashi, Shunji ; Nakatani, Fumihiko ; Imura, Yoshinori ; Naito, Yoichi ; Shimomura, Akihiko ; Doi, Toshihiko
Summary:
Background osteosarcoma is a rare, primary malignant bone tumour with limited available treatments for advanced or recurrent disease, resulting in a poor prognosis for patients. TAS-115 is a novel tyrosine kinase inhibitor under investigation in a phase I study in patients with solid tumours. We report data of osteosarcoma patients in the expansion cohort of this ongoing study. Patients and methods an analysis of this multicentre, open-label study was performed 6 months after the final patient was enrolled, and included patients aged ≥15 years, with unresectable or recurrent osteosarcoma, and who had refractory to standard therapy or for whom no standard therapy was available. TAS-115 650 mg/day was orally administered in a 5 days on/2 days off schedule. Results a total of 20 patients with osteosarcoma were enrolled. The most common adverse drug reactions (ADRs) were neutrophil count decreased (75%), aspartate aminotransferase increased (50%), and platelet count decreased (50%); 85% of patients had grade ≥ 3 ADRs. Long-term disease control (>1 year) with TAS-115 was achieved in three patients. The best overall response was stable disease (50%); no patient achieved a complete or partial response. Median progression-free survival was 3 months; 4-month and 12-month progression-free rates were 42% and 31%, respectively. Conclusion the safety and tolerability of TAS-115 and long-term disease stability for patients with unresectable or recurrent osteosarcoma were confirmed in this study, suggesting that TAS-115 is a promising novel therapy for advanced osteosarcoma patients. Trial registration number: JapicCTI-132333 (registered on November 8, 2013).
3
项与 Pamufetinib 相关的新闻（医药）2026-02-13
·新浪看点
*仅供医学专业人士阅读参考影像学与临床特征不匹配，临床困惑如何解答？撰文 | 呼吸频道编辑组间质性肺疾病（ILD）病因繁杂、临床表现缺乏特异性，其高度异质性与复杂性持续为临床诊断和治疗决策带来严峻挑战。近年来，随着对该疾病认知的不断深化，ILD诊疗领域正经历从传统认知局限向精准化、系统化管理的深刻变革。在由中华医学会呼吸病学分会指导，“医学界”主办的《“医”呼百应——2025呼吸年度进展》学术会议上，华中科技大学同济医学院附属同济医院张惠兰教授系统梳理了2025年ILD领域在疾病分类框架、诊断技术创新、多元化治疗策略及全程管理模式等方面的关键进展，旨在为临床实践提供基于最新证据的整合视角。深入——ILD的认知ILD是一组以肺间质炎症和纤维化为主要表现的异质性疾病，依照病因学、病程、临床-影像-病理和疾病行为可分为不同类别，具体类型超过200种[1-5]。2025年，ILD分类出现革新，一个基于病理和临床特征的分类框架将ILD分为间质性（纤维化型和非纤维化型）和肺泡填充性疾病两大类（图1）[6]。这一分类旨在从生物学本质出发，解决如肺泡蛋白沉积症等疾病中常见的影像学表现与临床症状严重度不匹配的临床困惑，通过强调病变累及部位的差异，更好地解释和预测患者的病理生理与预后。图1 新分类：间质性（纤维化型 vs 非纤维化型）和肺泡填充性疾病肺泡填充模式被明确界定由多种类型的细胞和液体异常填充肺泡和远端气道所引起。其主要包括三种常见模式：机化性肺炎（OP）、呼吸性细支气管炎间质性肺病（RB-ILD）和肺泡巨噬细胞肺炎（AMP），其中AMP作为一个更准确的术语取代了原有的“脱屑性间质性肺炎”，用于描述与吸烟等相关的肺泡内巨噬细胞广泛聚集。此外，肺泡填充模式还包括急/慢性嗜酸性粒细胞性肺炎（AEP/CEP）、肺泡蛋白沉积症（PAP）和脂质性肺炎（LP）等罕见模式。这些模式通常具有相对特征性的临床、影像及实验室检查表现，体现了对疾病更精准的认识，有助于推动ILD的精准诊断与个体化临床决策。图2OPa）病理特征（苏木精-伊红染色）：肺活检显示机化性肺炎模式，表现为肺泡管和肺泡腔内见息肉状、疏松的机化结缔组织栓子，分布均匀且呈斑片状。肺结构保留，未见间质纤维化。间质炎症不明显；b）轴向计算机断层扫描（CT）：显示双下叶实变和磨玻璃影，部分小叶不受累。c）和d）轴向CT及e）冠状面CT：显示机化性肺炎的“避让”模式：双侧磨玻璃影区域，左肺上叶前段可见反晕征，左肺上叶可见血管避让现象。f）经支气管冷冻肺活检：证实机化性肺炎与静脉及淋巴管的关系：在一支小叶间隔静脉的一侧可见边缘性的肺泡腔内息肉状疏松机化结缔组织栓子。图3 RB-ILDa）肺活检显示RB-ILD模式，可见以细支气管为中心的色素沉着的巨噬细胞积聚于细支气管内及周围肺泡腔。其主要病理特征是大量肺泡巨噬细胞充填肺泡；b）轴向计算机断层扫描（CT）：RB-ILD表现为双肺上叶及下叶尖段散布的小叶中心性磨玻璃结节。未见纤维化变形。图4 AMPAMP肺活检：a）肺泡因巨噬细胞而弥漫性充填扩张，间质伴轻度慢性炎症反应，形成一个生发中心。b）肺泡内过量巨噬细胞填充是主要病理特征，巨噬细胞可见不同程度色素沉积，可能伴嗜酸性粒细胞浸润。AMP的CT平扫影像：c）、d）显示双肺磨玻璃样密度影，背景表现为间隔旁型和小叶中心型肺气肿，并可见散在囊肿（主要分布于左肺上叶）。图5AEP/CEPAEP的低倍镜（A）与高倍镜（B）肺活检：肺泡腔内纤维蛋白样物质伴显著嗜酸性粒细胞浸润。慢性嗜酸性粒细胞性肺炎的手术肺活检（C）可见肺泡内大量嗜酸性粒细胞聚集及间质内混合性炎细胞浸润。轴位胸部CT（D）表现为多灶性磨玻璃影、实变伴小叶间隔增厚（白箭头）及双侧少量胸腔积液，未见纤维化征象。CEP模式的轴位与冠状位图像（E、F）：上肺野为主的周边性发磨玻璃影、伴反晕征的实变（白三角箭头）及小叶内间隔增厚。图6LP胸部轴位CT（A、B）：中下肺叶不规则脂肪密度影（白三角箭头）伴结构扭曲及小叶间隔增厚（白箭头）。外源性LP的肺活检标本（C）可见肺泡及间质内存在大小不一的脂质负荷巨噬细胞。与之相比，内源性LP（D）的巨噬细胞胞浆内可见更细小更均匀的空泡化改变。图7PAPPAP胸部CT（A）双肺肺泡区域出现铺路石征伴少量磨玻璃成分，呈对称性分布且胸膜下区域未受累。肺活检（B）无定形两亲性高碘酸-希夫阳性物质积聚。肺泡填充模式具体病理及影像学特征（图2-图7）精准——ILD的诊断人工智能（AI）与影像技术的深度融合在ILD诊断中发挥着日益重要的作用。AI能够快速识别影像学特征，并融合多模态临床数据进行建模，辅助医生实现精准诊断[7-10]。中国学者开展的CMM-IPF研究构建了基于AI系统和多模态数据的预后评估模型，显著提升了特发性肺纤维化（IPF）患者生存率预测的准确性[11]，为个体化诊疗路径的优化提供了重要依据。同时，肺部超声凭借其便捷的床旁应用价值，与CT联合使用可进一步提高对肺功能受损严重程度的预测准确性[12]。对疾病进程的深入理解揭示了干预的关键窗口。研究证实，ILD的病理进程远早于临床表现，早期IPF患者即使肺功能正常，其肺泡微环境已发生上皮细胞异常分化等关键病理改变[13]。间质性肺异常（ILA）作为ILD的影像前驱阶段，其发生与生命早期的肺功能下降及长期系统性炎症状态密切相关[14]。需特别注意的是，相较于急性炎症风暴，持续性炎症状态患者的累计发病率及总死亡率更高[15]。这揭示了ILD进展的核心驱动力在于未被彻底清除的慢性炎症所导致的反复损伤与异常修复，最终驱动肺功能呈阶梯式下降。同时，疾病分型日益精细，具有自身免疫特征的间质性肺炎（IPAF）是特发性ILDs中的一个重要分型，与典型的IPF相比，这类患者的肺泡灌洗液中，补体级联、急性期反应等炎症通路相关蛋白显著高表达[16]，提示IPAF具有独特的免疫特征。面对重症ILD患者，尤其是抗MDA5抗体阳性这类进展迅猛的疾病，如何实现及时、准确的预后判断是临床面临的巨大挑战。基于对肺内微环境与免疫病理机制的深刻理解，张惠兰教授团队创新性地将研究视角转向肺部呼出气体分析。研究识别出5种差异显著的挥发性有机物（VOCs）分子，其中与疾病严重度呈负相关的1，3-戊二烯和呈正相关的3-甲基十一烷，在评估抗MDA5阳性ILD的疾病严重程度和预测患者预后方面，展现出优于传统氧合指数、器官功能指标及共病评分的潜力[17]。此外，张惠兰教授总结了2025欧洲呼吸学会（ERS）年会上提出的从细胞衰老、纤毛功能到蛋白组学等多维度标志物[6]，以助了解其临床价值。图8 生物标志物丰富——ILD的治疗ILD的治疗策略正围绕两大重点深化发展：一是针对呼吸衰竭的支持治疗，二是旨在干预疾病进程的药物研发。一呼吸支持：由于ILD的病理生理基础与急性呼吸窘迫综合征（ARDS）等疾病存在本质不同，应审慎应用有创通气。数据显示[18]，接受有创机械通气的ILD患者死亡率显著增高。因此，临床中有创通气主要作为肺移植或体外膜肺氧合（ECMO）的桥接手段。相比之下，经鼻高流量氧疗展现出重要的优势，它能通过清洗呼吸道和减少死腔通量，并产生流量依赖性的气道正压，从而有效改善气体交换、降低呼吸频率，成为管理急性呼吸衰竭的重要无创支持方式[19]。二药物研发：全球ILD新药研发空前活跃，目前共有71个新药处于临床研究阶段，涉及38个靶点，主要定位于成纤维细胞。新药临床试验主要集中在Ⅰ期和Ⅱ期，其中化学新药数量占主导地位，且中国公司在研发数量上已居于领先地位。图9在研新药靶点为应对肺纤维化病因不明、异质性强的核心挑战，张惠兰教授总结了涵盖分子、细胞、病理到临床转化的“四类八策”药物研发创新策略，以供临床参考：▌第一类、分子靶点策略一：AI进行肺纤维化靶点筛选和药物设计该策略旨在通过人工智能技术挖掘疾病机制并开拓全新靶点。TNIK（TRAF2和NCK相互作用激酶）是全球首个由AI筛选的肺纤维化创新靶点，基于这一靶点设计的药物Rentosertib，已用于治疗特发性肺纤维化（IPF）。2025年公布的Ⅱa期临床结果显示，该药物在所有剂量水平均表现出良好的安全性，肺功能改善呈现剂量依赖性药效[20]。▌第二类、细胞行为策略二：靶向免疫细胞治疗肺纤维化该策略聚焦于调控在肺纤维化中起关键作用的免疫细胞。除上皮-间质转化（EMT）和内皮-间质转化（EndMT）外，巨噬细胞向成纤维细胞转化的现象日益受到关注。现有证据表明，单核来源的肺泡巨噬细胞（Mo-AM）在纤维化进程中扮演了关键的角色，其中，单核来源的CCR2+巨噬细胞在IPF患者肺内异常增多并促进纤维化[21,22]。抑制此类细胞活化、干预其分化和生存，成为重要的抗纤维化研究方向。磷酸二酯酶4B（PDE4B）在各种免疫细胞上高表达，其中巨噬细胞占60%[23,24]。PDE4B抑制剂那米司特（Nerandomilast）Ⅲ期研究提示，该药可显著缓解用力肺活量的下降[25]。此外，那米司特还能直接抑制人肌成纤维细胞活化、降低肺微血管内皮细胞通透性、并抑制上皮细胞纤维化相关蛋白的表达，共同构成了其抗纤维化的多重机制。巨噬细胞集落刺激因子（CSF1）及其受体（CSF1R）是调控单核细胞向巨噬细胞分化、存活及功能的核心信号轴。CSF1R小分子抑制剂EI-1071 通过抑制CSF1R，能够阻断单核细胞向巨噬细胞的分化，并抑制巨噬细胞释放促炎和促纤维化因子[26]。目前，该药的Ⅰ期临床试验已完成。策略三：调控整体细胞行为抗纤维化基于IPF病因未明、长期慢性炎症状态、衰老和异质性强等特点，寻找特效单靶点药物较为困难，调控整体细胞行为的作用逐渐显露。首先，利用基于多细胞共培养体系的高通量筛选平台，寻找能协同调节上述核心细胞行为的化合物；其次，在多种不同诱因诱导的肺纤维化动物模型中进行验证，以评估药物在异质性背景下的普适性；最后，开发与药物作用机制相关的生物标志物，用于临床试验中的患者分层与疗效预测。策略四：干细胞治疗肺纤维化目前绝大多数临床研究采用的间充质干细胞（MSC），其作用机制并非直接分化为新的肺泡，而是通过旁分泌效应，释放外泌体、细胞因子等生物活性物质，从而发挥强大的抗炎、抗纤维化及促进血管生成作用。目前，在肺纤维化领域，6种异体MSC产品已进入Ⅰ/Ⅱ期临床试验，全球已有16款MSC产品获批上市，适应症多为免疫相关疾病[27]。有中国学者开发了一种安全、有效且临床可行的雾化MSC来源的外泌体（hUCMSC-EVs）疗法，研究显示，雾化吸入人脐带MSC来源的外泌体在肺纤维化患者中耐受性良好，个别病例的影像学病灶出现改善[28]。支气管基底层细胞具有在损伤后增殖、迁移并分化为功能性肺泡上皮细胞的潜力。据此开发的自体细胞制剂（如REGEND001）已开展早期临床试验[29]。一项由研究者发起的小型探索性研究（n=3）初步报告，自体气道基底层干细胞治疗后，晚期IPF患者的肺功能和影像学获得改善[30]。张惠兰教授指出，其规模化应用和长期疗效仍需大规模临床试验证实。▌第三类、病理表现：胶原/成纤维细胞灶策略五：针对胶原的抗纤维化药物针对胶原代谢过程的直接干预，旨在跨越复杂的上游致病信号网络，直接干预细胞外基质的异常增多[31]。胶原蛋白富含脯氨酸，DWN-12088 是一种脯氨酰tRNA合成酶的小分子抑制剂，通过抑制脯氨酸合成而降低胶原蛋白水平，减缓肺纤维化的进展。ND-L02-s0201（BMS-986263）是一款靶向HSP47的小干扰RNA（siRNA）药物，可通过下调HSP47，抑制胶原折叠，减少胶原沉积，改善纤维化。单克隆抗体CHF10067则可通过抑制胶原在细胞外的组装，从而减缓纤维化的进展。▌第四类、改良与转化策略六：上市药物改构药物通过对吡非尼酮等有效药物进行理性结构修饰，以改善其药代动力学特性，提升疗效或降低不良反应。图10吡非尼酮改构药物治疗肺纤维化策略七：上市药物口服改吸入药物改变经典抗纤维化药物的给药途径，将吡非尼酮、尼达尼布等口服药改为吸入制剂，旨在提高肺部局部药物浓度，减少全身暴露，从而潜在提升疗效并改善安全性。以美国公司开发的吸入制剂为例，吸入型吡非尼酮（AP01）能够显著降低副作用的发生率；吸入型尼达尼布（AP02）在患者中耐受性良好，在达到相同肺组织药物浓度的前提下，吸入给药所需剂量仅为口服的1/160[32]。策略八：院内制剂转新药上市申请将临床显示一定疗效的中药院内制剂，按照现代新药标准进行系统研发与评价，进而申报新药。华中科技大学同济医学院附属同济医院张惠兰教授团队自主研发的“芪防肺纤颗粒”具有明确的抗炎和抗纤维化双重药理作用。该制剂历具有十年的真实世界临床应用经验，能够有效改善患者临床症状，且未见明显不良反应。2023年2月，该制剂获得湖北省药品监督管理局中药制剂批准文号（鄂药制备字Z20230001000），作为院内制剂在华中科技大学同济医学院附属同济医院规范使用；2024年8月，获得国家发明专利授权（专利号ZL 202310455882.X）。截至目前，“芪防肺纤颗粒”已累计服务患者逾1,300例。与此同时，针对ILD治疗的传统或新兴全身性治疗手段的循证依据也在更新。大规模观察性研究提示，冲击剂量糖皮质激素对急性加重的IPF患者可能无益，甚至对ICU/中级护理病房患者会增加死亡或出院到临终关怀的风险，这提示需审慎应用该类药物[33]；系统评价表明，利妥昔单抗虽可能改善结缔组织病相关间质性肺病（CTD-ILD）患者的肺功能，但在一氧化碳弥散能力或死亡率方面未显示出明确获益[34]。新靶点药物如抗转谷氨酰胺酶2单抗Zamplimab[35]、溶血磷脂酸受体1拮抗剂Admilparant[36,37]的临床试验仍在推进，但多靶点药物TAS-115在Ⅱb期研究中未能达到主要终点，提示临床转化仍需精准验证[38]。全面——ILD的管理ILD的临床管理正朝着更加标准化和全面化的方向发展。在诊断与风险分层方面，干预窗口已大幅前移至无症状或仅伴有轻微症状的ILA阶段。一项观察性研究显示，采用标准化随访路径（含虚拟访视）的ILA患者参与度与依从性良好[39]。在患者生存结局方面，前瞻性数据表明，近年来IPF患者的生存状况显著改善[40]，这一进展很可能得益于疾病认知的提高、筛查的推广以及抗纤维化药物的普及等综合因素。同时，全面评估并积极处理合并症也至关重要。一项大型分析提示，CTD-ILD患者发生静脉血栓栓塞症（VTE）的风险显著高于特发性ILD患者[41]，需制定个体化VTE预防策略并进行密切监测。在肺康复领域，研究证实，无论是高强度间歇训练（HIIT）还是中等强度持续训练（MICT），都能有效改善ILD患者的运动耐力[42]。且参与结构化肺康复项目能够明确改善患者的生理功能[43]，强调了肺康复在ILD综合治疗中的关键作用。小结2025年，ILD领域在认知与实践层面均取得了实质性推进。从疾病分类框架革新，到AI与多组学技术驱动的精准诊断，再到覆盖分子、细胞、病理等多维度的多元化治疗策略，以及贯穿疾病全程的系统化管理，共同勾勒出ILD诊疗的新范式。未来，整合这些进展，实现从早期识别、精准分型到个体化干预的闭环，是改善ILD患者预后的关键方向。专家简介张惠兰 教授华中科技大学同济医学院附属同济医院呼吸与危重症医学科主任国家重大公共卫生事件医学中心呼吸与重症救治基地主任教授，主任医师，博士后导师入选全球前2%顶尖科学家榜单2024中华医学会呼吸分会间质性肺疾病学组副组长中国医药教育协会诊断学专业委员会主任委员五年制医学人卫教材《诊断学》第10版副主编Thorax中文版副主编主持和参与多项国家自然科学基金，近五年以第一作者或通讯作者发表SCI论文10余篇，总影响因子233.3主要研究方向为重症间质性肺疾病的发病机制和治疗参考文献：[1]Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022;400(10354):769-786.[2]Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-748.[3]Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther. 2010;12(4):213. [4]Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group. What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51(5):1800692.[5]Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57.[6]Ryerson CJ, Adegunsoye A, Piciucchi S, et al. Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS/ATS statement. Eur Respir J. 2025;66(6):2500158. [7]G.H. Frobel, D. Johnston, C. Politoski,et al .Prevalence and Characteristics of Interstitial Lung Abnormalities by Radiologist Report and Quantitative Imaging Analysis in a Lung Cancer Screening Cohort.Am J Respir Crit Care Med 2025;211:A7677.[8]G.H.J. Kim, P. Teng, M. McNitt-Gray,et al. Rapid Screening Tool for Quantifying Pulmonary Fibrosis on High-resolution CT Scans [abstract]. Am J Respir Crit Care Med 2025;211:A1718.[9]J. Uribe, J. Kalra, M. Muelly,et al. Clinical Experience With the First FDA-Authorized Artificial Intelligence Tool in Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis [abstract]. Am J Respir Crit Care Med 2025;211:A1709. [10]A. Peltekian, K. Senkow, K. Biswas, et al.Radiomic Features Detect Interstitial Lung Disease in Patients With Systemic Sclerosis.Am J Respir Crit Care Med. 2025;211:A1707.[11]F. Li, Z. Chen, H. Zhang,etal. The Prognosis of Idiopathic Pulmonary Fibrosis in Chinese Patients: A Multi-Center and Multi-Modal Cohort Study [abstract]. Am J Respir Crit Care Med 2025;211:A1749. [12]T. Deiss, G. Gare, T.H. Fox, et al. Machine Learning Prediction of Disease Severity in Patients With Interstitial Lung Disease Based on Lung Ultrasound and CT Imaging [abstract]. Am J Respir Crit Care Med 2025;211:A1708.[13]A. Justet, T. Adams, J. Khoury, et al. Early IPF Is Characterized by a Dramatic Shift of the Epithelial and Endothelial Populations Within the Alveolar Niche [abstract]. Am J Respir Crit Care Med 2025;211:A7109. [14]Grudzinski K, Liu GY-H, Colangelo L, et al. Adult Life Course Trajectories of Lung Function and the Development of Interstitial Lung Abnormalities: The CARDIA Lung Study. Am J Respir Crit Care Med 2025; 211: A1001–A1001.[15]Sieiro Santos C.,Retuerto-Guerrero M,et al. OP0078 The role of inflammation in systemic sclerosis：CRP-associated phenotypes and prognostic implications.Annals of the Rheumatic Diseases.Volume 83, Supplement 1,2024.[16]E. Way, L.T. Ngo, I. Azeem, et al. Uncovering Molecular Distinctions Between IPAF and IPF: Proteomic Insights Into Inflammatory and Autoinflammatory Pathways [abstract]. Am J Respir Crit Care Med 2025;211:A2848.[17]Wang Y, Wang X, Yang L, et al. Exploring exhaled volatile organic compounds as potential biomarkers in anti-MDA5 antibody-positive interstitial lung disease. Mol Cell Biochem. 2025;480(7):4311-4323.[18]Ludovica Benuzzi,Roberta Ginanni,Gianni Misuri,et al.Outcomes of patients with interstitial lung disease admitted to ICU for acute respiratory failure.Eur Respir J 2024; 64: Suppl. 68, PA3488.[19]Jens Bräunlich, et al. Nasal High-Flow (NHF) Improves Ventilation in Patients with Interstitial Lung Disease (ILD)-A Physiological Study. ERJ Open Research 2024 10(suppl 13): 52.[20]Pun FW, Ozerov IV, Zhavoronkov A. AI-powered therapeutic target discovery. Trends Pharmacol Sci. 2023;44(9):561-572.[21]Brody SL, Gunsten SP, Luehmann HP, et al. Chemokine Receptor 2-targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial. Am J Respir Crit Care Med. 2021;203(1):78-89.[22]Misharin AV, Morales-Nebreda L, Reyfman PA, et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J Exp Med. 2017;214(8):2387-24[23]Su Y, Ding J, Yang F, et al. The regulatory role of PDE4B in the progression of inflammatory function study. Front Pharmacol. 2022;13:982130. [24]Konrad FM, Bury A, Schick MA, et al. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation. PLoS One. 2015;10(4):e0121725. [25]Facchinetti F, Civelli M, Singh D, er al. A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. Front Pharmacol. 2021;12:740803. [26]Meziani L, Mondini M, Petit B, et al. CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. Eur Respir J. 2018;51(3):1702120. [27]Yang S, Liu P, Jiang Y, et al. Therapeutic Applications of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis. Front Cell Dev Biol. 2021;9:639657.[28]Li M, Huang H, Wei X, et al. Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment. Signal Transduct Target Ther. 2025;10(1):179. [29]Wang X, Zhao Y, Li D, et al. Intrapulmonary distal airway stem cell transplantation repairs lung injury in chronic obstructive pulmonary disease. Cell Prolif. 2021;54(6):e13046.[30]Liu Z, Zheng Q, Li Z, et al. Epithelial stem cells from human small bronchi offer a potential for therapy of idiopathic pulmonary fibrosis. EBioMedicine. 2025;112:105538.[31]Yoon I, Kim S, Cho M, et al. Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl-tRNA synthetase 1. EMBO Mol Med. 2023;15(7):e16940.[32]Surber MW, Beck S, Pham S, et al. Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis. Pulm Pharmacol Ther. 2020;63:101938.[33]Shankar DA, Bosch NA, Jafarzadeh SR, et al. Association of Pulse Dose Corticosteroids With Outcomes Among Patients With Acute Exacerbations of Idiopathic Pulmonary Fibrosis. CHEST Pulm. 2025;3(4):100207.[34]A.L. Chavez Velasquez, A. Hameed, J. Caballero-Alvarado,et al.The Impact of Rituximab on Connective Tissue Disease-Associated Interstitial Lung Disease: A Comprehensive Systematic Review and Meta-Analysis [abstract]. Am J Respir Crit Care Med 2025;211:A1837.[35]G. Vitiello, S. Spennato, M. Salvadori, et al.Safety, Tolerability, and Pharmacokinetics of CHF10067 in Subjects With Idiopathic Pulmonary Fibrosis: A Phase Ib Study.Am J Respir Crit Care Med 2025;211:A2927.[36]T.M. Maher, M. Wijsenbeek, M. Kreuter, et al. Design and Rationale for a Phase 3 Trial of Admilparant (BMS-986278), An Oral Lysophosphatidic Acid Receptor 1 Antagonist, in Patients With Idiopathic Pulmonary Fibrosis: ALOFT-IPF[abstract]. Am J Respir Crit Care Med 2025;211:A3538.[37]F.J. Martinez, T.J. Corte, V. Cottin, et al. Design and Rationale of a Phase 3 Trial for Admilparant (BMS-986278), an Oral Lysophosphatidic Acid Receptor 1 Antagonist, in Patients With Progressive Pulmonary Fibrosis: ALOFT-PPF [abstract]. Am J Respir Crit Care Med 2025;211:A3543. [38]Y. Kondoh, R. Okuda, K. Tsubouchi, et al. TAS-115 (Pamufetinib) in Patients With Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype: Results of Phase 2b Randomized Clinical Trial [abstract]. Am J Respir Crit Care Med 2025;211:A2908.[39]J. Shaw, R. Gibson, T. Raj, et al. Early Experience of a Dedicated Clinical Pathway for Interstitial Lung Abnormalities (ILAs) [abstract]. Am J Respir Crit Care Med 2025;211:A3228.[40]W.F. Dai, J.H. Fisher, D. Assayag, et al. Baseline Characteristics and Survival Trends for Patients Diagnosed With Idiopathic Pulmonary Fibrosis Over 2016 - 2022 [abstract]. Am J Respir Crit Care Med 2025;211:A1732.[41]Z. Alwarawrah, H. El Sharu, T. Mubaydeen, et al. Venous Thromboembolism (VTE) Among Idiopathic Interstitial Lung Disease (ILD) and Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) Patients: A Large Cohort Comparative [abstract]. Am J Respir Crit Care Med 2025;211:A1728.[42]L. Dowman, A. May, C.J. Hill, et al. High Intensity Interval Training in Patients With Interstitial Lung Disease [abstract]. Am J Respir Crit Care Med 2025;211:A1038. [43]Seher Satar, Mustafa Engin Sahin,Zeynep Yesiloz, et al.Pulmonary rehabilitation in patients diagnosed with non-IPF-fibrosing interstitial lung disease receiving antifibrotic therapy. Eur Respir J 2024; 64: Suppl. 68, PA3187.
发布于：湖南
2023-12-13
The dynamics of the metastatic prostate cancer market are anticipated to change in the coming years owing to the rise in the number of companies taking interest in the development of specific drugs for mCRPC and nmCRPC along with increasing awareness and penetration of already approved prostate cancer drugs.
LAS VEGAS, Dec. 13, 2023 /PRNewswire/ -- DelveInsight's
Metastatic Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, metastatic prostate cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Metastatic Prostate Cancer Market Report
As per DelveInsight analysis, the total market size in the 7MM for metastatic castration-resistant prostate cancer (mCRPC) was estimated to be nearly
USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
In 2022, the United States held the highest market share for mCRPC and mCSPC in the 7MM, at
63% and 61%, respectively, followed by the EU4 countries and the UK.
As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly
8 million cases in 2022. These cases will increase during the study period, i.e., 2019–2032.
Leading metastatic prostate cancer companies such as
AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly and Company, Zr Pharma & GmbH, Bristol-Myers Squibb, Ipsen, Exelixis, Takeda, Janssen Research & Development, Tesaro, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point Biopharma, Xencor,
Essa Pharma
, Telix International, Bayer, Arvinas, and others are developing novel metastatic prostate cancer drugs that can be available in the metastatic prostate cancer market in the coming years.
The promising metastatic prostate cancer therapies in the pipeline include
HC-1119, Talazoparib, Enzalutamide, Niraparib, Boosted Oral Docetaxel, Masitinib, EPI-7386, Verzenio, 177Lu-PSMA-617, Capivasertib, I-131-1095, Proxalutamide (GT0918), MGC018, DS-7300, MVI-816, ARV-110, 177Lu-PNT2002 (PNT2002), Vudalimab (XmAb20717), 177Lu-DOTA-rosopatamab (TLX591), and others.
Established therapies in the metastatic prostate cancer market include Astella/Pfizer's and Jansenn's blockbuster products XTANDI and ZYTIGA, respectively, approved for metastatic patients for over a decade now. Even though
ZYTIGA's generics have entered the US market since 2019, and the EU since late 2022, leading to a drastic decline in the revenue mainly in the US, the product is extensively being evaluated in combination with novel emerging therapies, leading to an increase in patient share on the compound abiraterone acetate. Whereas,
Jansenn's XTANDI, the biggest revenue generator in the prostate cancer market, has witnessed stable growth since 2021 owing to increased competition.
Quantitatively mCRPC pipeline seems to be quite strong, however with recent failures/terminations of several trials of certain therapies in the past year, we have mentioned the most promising ones, which include
ESSA Pharma's EPI-7386, Macrogenics, and Daiichi's anti-B7-H3 Antibody Drug Conjugates, MGC-018 and DS-7300 respectively, Arvinas, AR-targeted PROTAC protein degrader, and Point Biopharma's Radioligand therapy. Except for Point Biopharma's therapy, none of these potential players have initiated a Phase III trial, even though Arvinas is planning to opt for an accelerated approval based on its Phase II data readout.
The landscape of mHSPC has evolved tremendously in the past decades. The treatment paradigm has shifted from androgen deprivation therapy (ADT) alone to doublet combinations comprising ADT with docetaxel or an androgen receptor inhibitor, and now triplet therapy involving all three classes of agents.
Apart from
XTANDI, ZYTIGA, and ERLEADA in the mCSPC market,
Bayer's NUBEQA is another rising contender with a strong uptake in a short period. Bayer is further strategizing to increase the prescription by volume for NUBEQA by label expansion in patients who are not eligible for chemotherapy in the ARANOTE Phase III trial.
PARP inhibitors such as
AKEEGA and TALZENNA are also currently being evaluated in the mHSPC space alone and with ARIs.
Novartis' radioligand therapy,
PLUVICTO approved in 2022, has generated an unexpected revenue from the third-line mCRPC setting, further plans to expand in an earlier line in mCRPC by 2024 in the United States. The approval of PLUVICTO has also marked a crucial advancement in treating progressive mCRPC, offering improved survival rates for those with limited treatment options.
The drug had an exceptionally robust initial market performance, garnering a stronger-than-expected uptake in the US. The drug is currently being studied in the Phase III PSMAddition study to see if that triplet combination is better than ADT and an androgen receptor signaling inhibitor alone in patients with mHSPC.
Discover which therapies are expected to grab the major metastatic prostate cancer market share @
Metastatic Prostate Cancer Market Report
Metastatic Prostate Cancer Overview
Prostate cancer, a form of malignancy specific to the prostate gland within the male reproductive system, can advance to a metastatic stage, spreading from the prostate to other areas of the body. This advanced stage is often referred to as metastatic or advanced prostate cancer, commonly extending to lymph nodes or bones. Prostate cancer symptoms can differ widely among individuals. Although some men might not experience any symptoms, typical signs may include the presence of blood in the urine or semen, painful ejaculation, discomfort or a burning sensation during urination, and various other related symptoms. The primary diagnostic method involves prostate-specific antigen (PSA) testing, which detects elevated PSA levels in individuals affected by prostate cancer or other prostate-related conditions. Screening processes may also include a digital rectal exam to identify any notable prostate tumors, alongside additional methods such as prostate ultrasound and MRI scans. However, a conclusive diagnosis typically necessitates a transrectal ultrasound-guided (TRUS) prostate tissue biopsy.
Metastatic Prostate Cancer Epidemiology Segmentation
As per DelveInsight analysis, the United States had the highest number of diagnosed prostate cancer cases in 2022, with approximately
2.9 million reported cases.
In 2022, total cases of metastatic CSPC/HSPC and metastatic CRPC were around
100K and
120K, respectively, in the 7MM. These cases are expected to increase by 2032.
The metastatic prostate cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalent Cases of Prostate Cancer
Total Diagnosed Cases of Prostate Cancer
Age-Specific Cases of Prostate Cancer
Total Diagnosed Cases of Prostate Cancer by Clinical Stages
Total Metastatic Cases of Prostate Cancer
Total Treated Cases of mCRPC
Total Treated Cases of mCSPC
Metastatic Prostate Cancer Treatment Market
Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a stage of prostate cancer that has spread to other parts of the body, such as lymph nodes or bones, and no longer responds to treatment that lowers testosterone. Despite currently approved therapeutics, mCRPC remains a terminal diagnosis with an aggressive disease course. ADT is a stalwart therapy for the initial treatment of metastatic disease. Unfortunately, most men in this situation will go on to develop mCRPC and require secondary systemic therapy. This disease state can be very challenging to treat.
Docetaxel was the only agent available for the treatment of mCRPC until 2010, which showed an increase in overall survival compared with the standard of care. It was approved in 2004 for mCRPC with prednisone. Patients failed to first-line docetaxel for many years, and no standard treatment option was approved. However, in the last few years, several drugs such as
JEVTANA, ZYTIGA, XTANDI, LYNPARZA, TALZENNA, AKEEGA, and others have received regulatory approval for mCRPC in the United States.
Most recently, PARP inhibitors have shown tremendous development in this area with AKEEGA (Janssen), followed by TALZENNA (Pfizer/Astellas Pharma) and LYNPARZA in combination (AstraZeneca/Merck) getting approved in mCRPC in 2023.
The approval of
PLUVICTO has also marked a crucial advancement in treating progressive mCRPC, offering improved survival rates for those with limited treatment options.
The drug had an exceptionally robust initial market performance, garnering a stronger-than-expected uptake in the US.
Quantitatively, the mCRPC pipeline seems to be quite strong. ADCs such as MGC018 and DS-7300 have both displayed encouraging results in clinical trials involving patients with mCRPC. However, except for Point Biopharma's therapy, none of these potential players have initiated a Phase III trial, even though Arvinas plans to opt for an accelerated approval based on its Phase II data readout.
Metastatic Castrate-Sensitive Prostate Cancer (mCSPC) is an advanced form of cancer in which cancer cells have spread from the prostate to other body areas. However, the patient is still sensitive to androgen deprivation therapy (ADT) (some mCSPC patients have never had ADT, while others may have had ADT but have recovered testicular function).
The backbone of all treatments in mCSPC is
androgen deprivation therapy (ADT) with medications that suppress the level of testosterone in the body because testosterone is the fuel for prostate cancer and gives the signals to grow and spread. Studies over the last decade have demonstrated that intensification of androgen deprivation with different treatment modalities correlates with prolongation of survival. The options for intensification include
docetaxel chemotherapy, different
androgen receptor-targeted agents, including
abiraterone acetate,
apalutamide, and
enzalutamide, and
radiation to the prostate. Most recently, the treatment paradigm for mHSPC shifted to triplet therapy,
NUBEQA
combined with ADT and chemotherapy. According to the findings presented at the ASCO GU 2023, the regimen should be considered the new standard of care for this patient population.
To know more about metastatic prostate cancer treatment guidelines, visit @
Metastatic Prostate Cancer Management
Metastatic Prostate Cancer Pipeline Therapies and Key Companies
Capivasertib (AZD 5363): AstraZeneca
Bavdegalutamide (ARV-110): Arvinas
MVI-816 (pTVG-HP): Madison Vaccines
PT-112: Phosplatin Therapeutics
HC-1119: Hinova Pharmaceuticals
OPDIVO (nivolumab): Bristol Myers Squibb
KEYTRUDA (Pembrolizumab/MK-3475): Merck
MGC018 (vobramitamab duocarmazine): MacroGenics
DS-7300: Daiichi Sankyo
Ceralasertib: AstraZeneca
Ladiratuzumab vedotin: Seagen/Merck
BMS-986218: Bristol-Myers Squibb
TAS-115: Taiho Pharmaceutical
ModraDoc006/r: Modra Pharmaceuticals
Vudalimab: Xencor
(Lu-177) - PNT2002: Point Biopharma
LNTH-1095 (MIP-1095): Lantheus Holdings
ZEN-3694: Zenith Epigenetics
EPI-7386: Essa Pharma
177Lu-DOTA-rosopatamab: Telix Pharmaceuticals
Proxalutamide: Kintor Pharmaceutical
Masitinib: AB Science
VERZENIO (Abemaciclib/LY2835219): Eli Lilly and Company
CABOMETYX (cabozantinib): Exelixis
Learn more about the FDA-approved drugs for metastatic prostate cancer @
Drugs for Metastatic Prostate Cancer Treatment
Metastatic Prostate Cancer Market Dynamics
The dynamics of the metastatic prostate cancer are expected to change in the coming years. Before 2010,
docetaxel was the primary therapeutic option for metastatic castration-resistant prostate cancer (mCRPC), demonstrating improved overall survival compared to the established standard of care. Its approval in 2004, alongside prednisone, marked a
milestone in mCRPC treatment. Following initial docetaxel therapy failure, patients faced a dearth of approved second-line treatments for numerous years. However, recent years have witnessed regulatory approvals of multiple drugs in the United States for mCRPC, transforming the treatment landscape.
Notably, medications such as
JEVTANA, ZYTIGA, XTANDI, LYNPARZA, TALZENNA, AKEEGA, and several others have gained approval. Of late, significant advancements have emerged in the realm of mCRPC, particularly with PARP inhibitors.
AKEEGA from Janssen, TALZENNA jointly developed by
Pfizer and Astellas Pharma, and the combination of
LYNPARZA by AstraZeneca and Merck garnered approval in 2023, showcasing remarkable progress in this domain.
PLUVICTO's approval is a significant leap forward in the management of progressive metastatic castration-resistant prostate cancer, bringing
improved survival rates to patients with limited treatment alternatives. The drug witnessed an exceptional and robust initial performance in the US market, exceeding expectations.
In numerical terms, the pipeline for metastatic castration-resistant prostate cancer appears robust. Antibody-drug conjugates like
MGC018 and DS-7300 have demonstrated promising outcomes in clinical trials among mCRPC patients. Nevertheless, except for
Point Biopharma's treatment, the majority of these prospective treatments have yet to commence a Phase III trial. Despite this,
Arvinas intends to pursue an expedited approval pathway leveraging its Phase II data for regulatory approval.
Scope of the
Metastatic Prostate Cancer
Market Report
Therapeutic Assessment: Metastatic Prostate Cancer current marketed and emerging therapies
Metastatic Prostate Cancer
Market Dynamics: Key Market Forecast Assumptions of Emerging Metastatic Prostate Cancer Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Metastatic Prostate Cancer Market Access and Reimbursement
Discover more about metastatic prostate cancer drugs in development @
Metastatic Prostate Cancer Clinical Trials
Table of Contents
Related Reports
Prostate Cancer Epidemiology Forecast
Prostate Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and prostate cancer epidemiology trends.
Metastatic Prostate Cancer Pipeline
Metastatic Prostate Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic prostate cancer companies, including
AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis
, among others.
Metastatic Castration-Resistant Prostate Cancer Market
Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic castration-resistant prostate cancer companies including
AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others.
Metastatic Hormone-Refractory Prostate Cancer Pipeline
Metastatic Hormone-Refractory Prostate Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key metastatic hormone-refractory prostate cancer companies, including
AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Contact Us
Shruti Thakur
[email protected]
+91-9650213330
Logo:
SOURCE DelveInsight Business Research, LLP
临床3期上市批准临床结果临床2期
2023-05-25
The prevalence of idiopathic pulmonary fibrosis has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of idiopathic pulmonary fibrosis and the growing research and development activities to develop novel therapies to treat idiopathic pulmonary fibrosis to drive the market. The companies developing the potential therapies in the last stage of development include
FibroGen, Boehringer Ingelheim, and several others.
LAS VEGAS, May 25, 2023 /PRNewswire/ -- DelveInsight's
'
Idiopathic Pulmonary Fibrosis Pipeline Insight – 2023
' report provides comprehensive global coverage of pipeline idiopathic pulmonary fibrosis therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the idiopathic pulmonary fibrosis pipeline domain.
Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report
DelveInsight's idiopathic pulmonary fibrosis pipeline report depicts a robust space with
80+ active players working to develop
100+ pipeline therapies for idiopathic pulmonary fibrosis treatment.
Key idiopathic pulmonary fibrosis companies such as
FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd, Ark Biosciences, Ocean Biomedical, and others are evaluating new idiopathic pulmonary fibrosis drugs to improve the treatment landscape.
Promising idiopathic pulmonary fibrosis pipeline therapies in various stages of development include
Pamrevlumab, Treprostinil, Nitric oxide inhalation - INOpulse, MN-001 (tipelukast), VAY736, ENV-101, PLN-74809, ND-L02-s0201, KD025, GKT137831, AP 01, LYT-100, TAS-115, BMS-986278, GB0139, CSL312, CC-90001, C21, BI1015550, ZSP1603, HEC585, Jaktinib Dihydrochloride Monohydrate, Ifenprodil, HZN-825, DWN12088, MG-S-2525, Saracatinib, LTI-03, BBT-877, AZD5055, KIN001-IPF, Treprostinil palmitil inhalation powder (TPIP), Brilaroxazine, ANPA 0073, SHR 1906, AK 3280, OCF 203, and others.
In
May 2023, Kinarus Therapeutics announced the signing of a strategic convertible loan agreement for a
CHF 1.5 million investment by
ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China ("CDIM"). Further, this agreement forms the basis for discussions on the introduction, development and commercialization of
KIN001 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in China. Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, introduced CDIM to Kinarus.
In April 2023, AGC Biologics announced it signed a service agreement with
The Jikei University in Japan. Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan.
In February 2023, Insilico Medicine announced that the US Food and Drug Administration (FDA) had granted
Orphan Drug Designation to
INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
In February 2023, Arrowhead Pharmaceuticals Inc. announced that it had dosed the first subjects in a Phase I/IIa clinical trial of ARO-MMP7, the company's investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).
In February 2023, South Korea's Daewoong Pharmaceutical secured an exclusive licensing agreement with
CS Pharmaceuticals for a first-in-class PRS inhibitor Bersiporocin in the Greater China region, including mainland China, Hong Kong, Taiwan, and Macau. Under this agreement, CSP will in-license
Bersiporocin for Idiopathic Pulmonary Fibrosis (IPF) and potentially other fibrotic indications for a total consideration of up to
$336 million, including up to
$76 million in upfront and development milestone payments and double-digit royalties on Net Sales.
In January 2023, Insilico Medicine announced the positive topline results of safety, tolerability, and pharmacokinetics (PK) from the Phase 1 clinical trial of
INS018_055, a potential first-in-class drug discovered by Insilico's end-to-end AI platform for idiopathic pulmonary fibrosis (IPF).
In January 2023, Pliant Therapeutics announced 12-week
interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of
bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF).
In December 2022, Vallon Pharmaceuticals announced that they entered into a
definitive agreement (the "Merger Agreement") pursuant to which
GRI Bio will merge with a wholly-owned subsidiary of Vallon in an all-stock transaction (the "Merger"). The combined company will focus on advancing GRI Bio's innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases. Following the closing of the Merger, the combined company is expected to operate under the name
"GRI Bio, Inc."
Request a sample and discover the recent advances in idiopathic pulmonary fibrosis drug treatment @
Idiopathic Pulmonary Fibrosis Pipeline Report
The idiopathic pulmonary fibrosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage idiopathic pulmonary fibrosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the idiopathic pulmonary fibrosis clinical trial landscape.
Idiopathic Pulmonary Fibrosis Overview
Idiopathic pulmonary fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that primarily affects middle-aged and older adults. It affects lung tissue by thickening, stiffening, or persistent and progressive scarring that worsens irreversibly over time. Scarring affects the air sacs of IPF patients, decreasing the amount of oxygen that enters the circulation. With less oxygen in the blood, ordinary tasks such as walking can cause dyspnea. This set of lung illnesses is also known as 'Diffuse Parenchymal Lung Diseases,' and it is distinguished by a broader umbrella of 'Interstitial Lung Diseases (IDLs)'. The cause of IPF is uncertain; experts believe the condition is caused by a mix of hereditary and environmental factors. There is a significant chance that genetic variations enhance a person's risk of acquiring IPF and then being exposed to environmental variables that aggravate the condition. However, much remains unknown about this new field of study.
Find out more about drugs for idiopathic pulmonary fibrosis @
New Idiopathic Pulmonary Fibrosis Drugs
A snapshot of the Idiopathic Pulmonary Fibrosis Pipeline Drugs mentioned in the report:
Learn more about the emerging idiopathic pulmonary fibrosis pipeline therapies @
Idiopathic Pulmonary Fibrosis Clinical Trials
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
The idiopathic pulmonary fibrosis pipeline report proffers an integral view of idiopathic pulmonary fibrosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report
Coverage: Global
Idiopathic Pulmonary Fibrosis Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Idiopathic Pulmonary Fibrosis Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
By Route of Administration: Oral, Parenteral, Intravitreal, Subretinal, Topical
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
By Mechanism of Action: Connective tissue growth factor inhibitors, 5-lipoxygenase inhibitors, Leukotriene D4 receptor antagonists, Leukotriene receptor antagonists, Phospholipase C inhibitors, Thromboxane A2 receptor antagonists, Type 3 cyclic nucleotide phosphodiesterase inhibitors, Type 4 cyclic nucleotide phosphodiesterase inhibitors, Integrin alphavbeta1 inhibitors, Integrin alphaVbeta6 inhibitors, Antibody-dependent cell cytotoxicity, Interleukin 4 receptor antagonists, SMO protein inhibitors, Galectin 3 inhibitors
Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd, Ark Biosciences, Ocean Biomedical, and others.
Key Idiopathic Pulmonary Fibrosis Pipeline Therapies: Pamrevlumab, Treprostinil, Nitric oxide inhalation - INOpulse, MN-001 (tipelukast), VAY736, ENV-101, PLN-74809, ND-L02-s0201, KD025, GKT137831, AP 01, LYT-100, TAS-115, BMS-986278, GB0139, CSL312, CC-90001, C21, BI1015550, ZSP1603, HEC585, Jaktinib Dihydrochloride Monohydrate, Ifenprodil, HZN-825, DWN12088, MG-S-2525, Saracatinib, LTI-03, BBT-877, AZD5055, KIN001-IPF, Treprostinil palmitil inhalation powder (TPIP), Brilaroxazine, ANPA 0073, SHR 1906, AK 3280, OCF 203, and others.
Dive deep into rich insights for new drugs for idiopathic pulmonary fibrosis treatment; visit @
Idiopathic Pulmonary Fibrosis Medications
Table of Contents
For further information on the idiopathic pulmonary fibrosis pipeline therapeutics, reach out @
Idiopathic Pulmonary Fibrosis Drug Treatment
Related Reports
Idiopathic Pulmonary Fibrosis Market
Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key idiopathic pulmonary fibrosis companies, including
FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLC, among others.
Idiopathic Pulmonary Fibrosis Epidemiology Forecast
Idiopathic Pulmonary Fibrosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and idiopathic pulmonary fibrosis epidemiology trends.
Pulmonary Fibrosis Pipeline
Pulmonary Fibrosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary fibrosis companies, including
Roche, Boehringer Ingelheim, Galecto Biotech, Cipla, Gilead Sciences, Fibrogen, Bristol-Myers Squibb, among others.
Pulmonary Fibrosis Market
Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary fibrosis companies, including
Roche, Boehringer Ingelheim, Galecto Biotech, Cipla, Gilead Sciences, Fibrogen, Bristol-Myers Squibb, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP
临床1期引进/卖出孤儿药临床2期
100 项与 Pamufetinib 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 骨肉瘤 | 临床3期 | 日本 | 2021-01-14 | |
| 进行性纤维化间质性肺病 | 临床2期 | 日本 | 2021-10-26 | |
| 特发性肺纤维化 | 临床2期 | 日本 | 2018-04-24 | |
| 前列腺癌 | 临床2期 | 日本 | 2016-10-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 进行性纤维化间质性肺病 platelet-derived growth factor receptor (PDGFR) | colony stimulating factor 1 receptor (CSF1R) | vascular endothelial growth factor receptor (VEGFR | 243 | 觸衊蓋鹹襯鑰繭鏇選廠(鏇選構獵遞繭鑰衊壓鹹) = 選糧糧獵淵範範衊積獵 顧餘簾簾糧夢餘顧壓鏇 (鏇窪願顧窪蓋鏇構網襯 ) | 不佳 | 2025-05-16 | ||
觸衊蓋鹹襯鑰繭鏇選廠(鏇選構獵遞繭鑰衊壓鹹) = 鬱獵衊齋遞鏇襯願範築 顧餘簾簾糧夢餘顧壓鏇 (鏇窪願顧窪蓋鏇構網襯 ) | |||||||
临床2期 | 50 | TAS-115 with abiraterone acetate | 繭願繭觸糧廠鑰願鹽壓(鏇糧選壓觸鹽鬱膚獵憲) = 23% in cohort B 遞願鹹廠餘壓簾齋齋製 (齋餘餘製齋艱鹹襯鬱鏇 ) 更多 | 积极 | 2019-02-26 | ||
TAS-115 400 or 600 mg/day |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用